Another study conducted on 198 AML patients by Kornblau et al. showed that high BCL-2 protein levels may result in a lowered median survival in the case of favorable/intermediate cytogenetics, but a higher survival in the case of poor cytogenetics [49]. The gene discussed is BCL2; the disease is acute myeloid leukemia.